Mifepristone

Generic Name: Mifepristone

Brand Names: Korlym, Mifegymiso

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₅NO_₂

CAS Number: 84371-65-3

Unique Ingredient Identifier: 320T6RNW1F

Background: Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary c...

Indication: For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.

Associated Conditions: Hyperglycemia

Associated Therapies: Medically induced abortion

Clinical Trials

Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis

Phase 2

Completed

Conditions: Adenomyosis

Interventions: Drug: Placebo
Drug: Mifepristone

First Posted Date: 2018-05-09

Last Posted Date: 2019-10-03

Lead Sponsor: xinmei zhang

Target Recruit Count: 134

Registration Number: NCT03520439

Locations: 🇨🇳
Women's Hospital of Zhejiang Medical University, Hangzhou, Zhejiang, China

CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Matching Placebo of CORT125134
Drug: CORT125134
Drug: Mifepristone
Drug: Prednisone
Drug: Glucose

First Posted Date: 2018-04-26

Last Posted Date: 2019-08-09

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 130

Registration Number: NCT03508635

Locations: 🇬🇧
Quotient Clinical, Nottingham, Nottinghamshire, United Kingdom

Medication Abortion Via Pharmacy Dispensing

Phase 4

Completed

Conditions: Pregnancy Related
Abortion Early

Interventions: Other: Training on mifepristone dispensing
Drug: Mifepristone

First Posted Date: 2017-10-25

Last Posted Date: 2021-07-12

Lead Sponsor: Daniel Grossman

Target Recruit Count: 326

Registration Number: NCT03320057

Locations: 🇺🇸
Obstetrics and Gynecology Family Planning Clinic at University of California Davis, Sacramento, California, United States
🇺🇸
Planned Parenthood Great Northwest, Hawai'i, Alaska, Indiana, Kentucky, Tacoma, Washington, United States
🇺🇸
Women's Health Services at University of California San Diego, San Diego, California, United States

and more 3 locations

Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy in Burkina Faso

Phase 3

Conditions: Medical; Abortion, Fetus

Interventions: Drug: Mifepristone
Drug: Misoprostol

First Posted Date: 2017-08-31

Last Posted Date: 2019-05-30

Lead Sponsor: Gynuity Health Projects

Target Recruit Count: 100

Registration Number: NCT03269279

Locations: 🇧🇫
CHUYO, Ouagadougou, Burkina Faso
🇧🇫
CMA Boromo, Boromo, Burkina Faso
🇧🇫
CHR Ouahigouya, Ouahigouya, Burkina Faso

and more 1 locations

Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Mifepristone

First Posted Date: 2017-08-23

Last Posted Date: 2018-02-23

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 48

Registration Number: NCT03258372

Locations: 🇺🇸
SeaView Reserch, Miami, Florida, United States

Glucocorticoid Antagonist Treatment for Tobacco Use Disorder

Early Phase 1

Terminated

Conditions: Nicotine Dependence

Interventions: Drug: Placebo
Drug: Mifepristone

First Posted Date: 2017-08-14

Last Posted Date: 2019-05-28

Lead Sponsor: Yale University

Target Recruit Count: 8

Registration Number: NCT03248713

Locations: 🇺🇸
Veterans Affairs Hospital, West Haven, Connecticut, United States

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Triple Negative Breast Neoplasms
Breast Cancer

Interventions: Drug: Pembrolizumab
Drug: Mifepristone

First Posted Date: 2017-07-21

Last Posted Date: 2024-07-31

Lead Sponsor: University of Chicago

Target Recruit Count: 74

Registration Number: NCT03225547

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Comparing Two Medical Treatments for Early Pregnancy Failure.

Phase 4

Terminated

Conditions: Early Pregnancy Failure

Interventions: Drug: Mifepristone
Drug: Misoprostol

First Posted Date: 2017-07-11

Last Posted Date: 2020-05-01

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 342

Registration Number: NCT03212352

Locations: 🇳🇱
Amphia Hospital, Breda, Netherlands
🇳🇱
Rijnstate, Arnhem, Gelderland, Netherlands
🇳🇱
Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands

and more 10 locations

Mifepristone and Misoprostol Compared With Misoprostol Alone for Second Trimester Abortion

Phase 4

Conditions: Second Trimester Abortion

Interventions: Drug: Placebo
Drug: Mifepristone
Drug: Misoprostol

First Posted Date: 2017-02-06

Last Posted Date: 2017-02-06

Lead Sponsor: Rambam Health Care Campus

Target Recruit Count: 200

Registration Number: NCT03044093

Locations: 🇮🇱
Rambam Medical Campus, Haifa, Israel

S9005 Mifepristone in Meningioma

Phase 3

Completed

Conditions: Meningioma

Interventions: Other: Placebo
Drug: Mifepristone

First Posted Date: 2017-01-10

Last Posted Date: 2019-12-23

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 193

Registration Number: NCT03015701

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy